22.6 C
New York
Saturday, June 13, 2026

Tag: brain

newssourceFORcompanyinformationcontent1marketreleases

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Valeo – Résultats du 1er semestre 2025

CP résultats S1 2025 Wiztrust

Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

Exhale Expands THCA Collection With Two Best THCA Flower Strains: Godfather OG and Hawaiian Haze

Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features. 
Exhale Wellness, a leading hemp-based wellness brands, introduced two new THCA flower strains in July 2025. Read more about their features.

A New Chapter of Bold Leadership and Unstoppable Growth

LEHI, Utah, July 23, 2025 /CNW/ -- Amare Global, The Mental Wellness Company™, is pleased to announce a powerful new chapter; effective immediately, David...

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

Sparkling Ice and Giant Eagle join forces to support military veterans struggling with invisible wounds of war

Sparkling Ice and Giant Eagle have teamed up to sponsor a PTSD service dog through K9s For Warriors, whose mission is to end veteran suicide.

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

IIHM Reveals First-Ever Hospitality AI Awards, Hosts Landmark Debate on Tech & Human Touch

KOLKATA, India, July 22, 2025 /PRNewswire/ -- The International Institute of Hotel Management (IIHM), India's most internationally recognized hospitality education brand, marked World AI...

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBrain

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers